4 Gene Therapy Stocks to Watch in 2017
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Your trusted source for investing success
Your trusted source for investing success
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of each.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR
From precision meds to the ongoing CRISPR-Cas9 saga, here are the top genetics news stories of 2016. We expect each to have major ripple effects in 2017 and beyond.
The following news stories made headlines in 2016, since they triggered major stock sell-offs in the sector. But it’s not all bad news: a few key events also caused biotech to rally.
We bring you Brad Loncar’s take on the biotech industry, including a couple of companies he is keeping an eye on.
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.
Gene-editing company CRISPR Therapeutics (NASDAQ:CRSP) has priced their initial public offering and now, interested investors can purchase a piece.
By Vivien Diniz
Editas Medicine’s share price went on a tear following its IPO in February. In the last two days, however, it’s dropped 36 percent. Here’s why.
